-
Johnson & Johnson Medical Joins Hands with Beijing Bethune Charity Foundation to Advocate Comprehensive Management of Heart and Brain Health
Time of Update: 2021-07-15
Participating experts and scholars advocated the promotion of the concept of comprehensive management of cardiovascular and cerebrovascular diseases, advocated early diagnosis and treatment of heart and brain diseases, and the establishment of a multi-level medical payment system to vigorously promote the development of the "Healthy China 2030" plan.
-
Numai Medical completes more than 100 million U.S. dollars in Series C financing to accelerate the research and development of structural heart disease interventional products
Time of Update: 2021-07-14
Recently, Shanghai NewMed Medical Technology Co. , Ltd. announced the completion of more than 100 million U. S. dollars in Series C financing. This round of financing was led by Temasek, Yunfeng,
-
Donge Ejiao's performance in 2020 turned losses into profits?
Time of Update: 2021-07-14
72% of profits; donkey breeding and sales achieved revenue of 296 million yuan, Accounted for 8.
At the same time, according to crawler data, in 2020, Tmall platform Dong Ejiao GMV (total turnover) has reached 469 million yuan, an increase of 109% year-on-year.
-
Genetron Biotech's financial report and operating status for the fourth quarter and full year of 2020
Time of Update: 2021-07-14
In 2020, the revenue of HCCscreenTM and IVD products (including Genetron S5 instrument and lung cancer 8-gene kit) in LDT testing will increase significantly The gross profit margin in the fourth quarter was 62.
-
Jianshi Medical and Shockwave Medical establish a joint venture company to introduce "intravascular shock wave" calcification treatment technology
Time of Update: 2021-07-14
With the acquisition of medicated chocolate balloon technology and the establishment of a joint venture with Shockwave, HealthScience already has two innovative products for the treatment of peripheral and coronary artery diseases .
-
Covestro joins hands with REnato lab to launch the "Circular Design Guide" for the electrical, electrical and home appliance industries
Time of Update: 2021-07-14
Covestro and REnato lab, a consulting company, launched the "Circular Design Guide" for the electrical, electrical and home appliance industries, aiming to help customers find more sustainable solutions and help designers and developers create next-generation products that are more in line with the circular economy .
-
Zhong Suansui resigns from the post of chairman of the subsidiary of Yangshengtang
Time of Update: 2021-07-14
According to an enterprise investigation, Youdao Biopharmaceutical (Hangzhou) Co. , Ltd. has recently undergone an industrial and commercial change. The legal representative was changed from Liang
-
Deck Pharmaceuticals Announces 2020 Results, Its Valuation under Lisence-in Model Doubles 14 Times in Three Years
Time of Update: 2021-07-14
Due to similar business models, Deqi Pharmaceuticals has been benchmarked by many investors with Zai Lab, whose stock price has risen approximately 6 times over the past three years .
-
Chuangsheng Group announced the appointment of Dr. Xichen Zhang as Senior Vice President of Production and Dr. Jie Yu as Senior Vice President of Pharmacokinetics and Translational Medicine
Time of Update: 2021-07-14
Before joining Chuangsheng Group, he served as Amgen's product quality director, leading the quality work of multiple new drug development projects in different clinical development stages including Sensipar/Mimpara, Parsabiv, AMG223, AMG282, AMG420, AMG479, AMG592 and AMG510 .
-
Deck Pharmaceuticals Announces 2020 Annual Results Progress
Time of Update: 2021-07-14
Progress after the reporting period In January 2021, the company submitted an IND application for the Phase I clinical trial of ATG-019 for the treatment of solid tumors and lymphoma to NMPA .
-
CStone's 2020 financial report: a variety of inhibitors with annual revenue of over 1 billion yuan will be listed soon
Time of Update: 2021-07-14
After deducting the effect of changes in the fair value of preferred stock conversion characteristics and share-based payment expenses, the loss was RMB 865 million .
In 2021, CStone Pharmaceuticals plans to have 4 commercial listings, including pratinib (RET inhibitor), avatinib (KIT/PDGFRA inhibitor), and Avonib (IDH1 inhibitor) listed in China.
-
Clover Biology and Dynavax New Crown Vaccine Candidate Global Phase II/III Clinical Trial Completes First Volunteer Vaccination
Time of Update: 2021-07-14
Ryan Spencer, CEO of Dynavax, said: "We are very pleased to see the completion of the first batch of volunteers in the SPECTRA project, which will have the opportunity to prove the safety and effectiveness of the clover bio-new crown vaccine candidate when used in combination with CpG 1018 plus aluminum adjuvant.
-
WuXi Biologics has outstanding performance in 2020
Time of Update: 2021-07-14
► 40. 9% to RMB 5. 612 billion ► 52. 7% to 2. 533 billion yuan ► 67. 5% to RMB 1. 693 billion ► 45. 1% and 30. 2% ► 71. 7% to 94. 6 million U. S. dollars ► 122. 0% to 11. 32 billion U. S. dollars ►
-
The internal dispute of Gao Tejia ends, and the second shareholder Dray wins
Time of Update: 2021-07-14
At that time, shareholders other than the major shareholder Jin Huili elected Bian Zhuang, the second shareholder of Gao Tejia, chairman of Delai, to become the chairman of Gao Tejia, and Sun Jialin as the general manager; Jin Huili, the chairman of Hongrui Huang Qing and Zhu Shiyao were dismissed.
-
Jingtai Technology joins hands with Qingyu Pharmaceutical to jointly launch a number of AI anti-tumor pipeline research and development
Time of Update: 2021-07-14
As the world's leading artificial intelligence (AI) drug research and development company, Jingtai Technology will take AI, high-precision computational chemistry and other advanced technologies as the core, combining expert experience and drug experimental research capabilities to provide Qingyu Medicine with an "integrated" Drug discovery services reduce the cost and cycle of drug development and increase the success rate .
-
Nature Pharmaceutical Announces Pricing and Listing of Initial Public Offering
Time of Update: 2021-07-14
The company's common stock has been approved for trading on the Nasdaq Global Market and will begin public trading on the Nasdaq on March 23, 2021, Eastern Time, under the stock code "UPC" .
Without deducting underwriter discounts and related issuance expenses, the company's public offering is expected to raise a total of US$25 million .
-
Tianjing Bio will hold 2021 Investor R&D Day
Time of Update: 2021-07-14
Tianjing Bio is a biopharmaceutical company in the clinical stage.
It is committed to the target biological research of innovative biopharmaceuticals, antibody technology, and clinical development and product commercialization in China and the United States.
Zhu Jielun, and Chief Commercial Officer Mr.
-
Yahong Pharmaceutical and Guokong Lecheng signed a strategic cooperation agreement
Time of Update: 2021-07-14
According to the agreement, the two parties will integrate resources, introduce and provide innovative medicinal equipment projects with great potential for Boao Lecheng Medical Tourism Pioneer Zone, promote the rapid implementation of the projects, and actively participate in real-world research pilot work to help Lecheng Pioneer District become a world-class innovation The gateway to China for medical equipment .
-
Cai said the performance of Livzon Group is currently weak, can the overweight Chinese medicine sector break the situation?
Time of Update: 2021-07-14
8 billion yuan?Livzon Group stated in the announcement that the company can cooperate with Tianjin Tongrentang at the level of traditional Chinese medicine business, and can also realize corresponding investment income through its cash dividends or initial public offerings .
-
Jiahe Biotech released its 2020 annual results today
Time of Update: 2021-07-14
Jiahe Biotech is committed to becoming a biopharmaceutical engine for discovery, research, development, production and commercialization of innovative therapies, and strives to build a biopharmaceutical innovation integrated company with the entire value chain and the entire industry chain .
